MacroGenics Inc. is a clinical-stage biotechnology company that develops and commercialises innovative antibody-based therapies for cancer and other diseases. Its operations are conducted on an international scale, with a global reach in various markets.
MacroGenics is part of the biopharmaceutical sector. Its technology platforms and expertise in protein engineering have enabled it to create several vital product candidates. It has also entered into strategic collaborations with global pharmaceutical and biotechnology companies.
Monitor the MGNX share price by adding it to your eToro watchlist.